- Home
- MUFG vs AZN Comparison
MUFG vs AZN Comparison
Compare MUFG & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUFG | AZN |
|---|---|---|
| Founded | 1880 | 1992 |
| Country | Japan | United Kingdom |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.1B | 250.7B |
| IPO Year | 2002 | 1995 |
Fundamental Metrics
Financial Performance| Metric | MUFG | AZN |
|---|---|---|
| Price | $24.07 | $162.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.4M | ★ 3.1M |
| Earning Date | 05-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.32% | 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.62 | $10.34 |
| Revenue Next Year | $10.12 | $6.43 |
| P/E Ratio | ★ $25.47 | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.65 | $72.90 |
| 52 Week High | $24.26 | $212.71 |
Technical Indicators
Market Signals| Indicator | MUFG | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 69.30 | 49.74 |
| Support Level | $21.50 | $164.06 |
| Resistance Level | N/A | $170.18 |
| Average True Range (ATR) | 0.31 | 2.83 |
| MACD | 0.13 | 0.51 |
| Stochastic Oscillator | 96.39 | 61.22 |
Price Performance
Historical ComparisonAbout MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.